Boehringer Ingelheim

Boehringer Ingelheim is a leading research-based pharmaceutical company founded in 1885 in Ingelheim, Germany. The family-owned business focuses on developing innovative medicines for human and animal health. Boehringer Ingelheim operates across three core business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

In the Human Pharma segment, the company concentrates on therapeutic areas such as cardiology, oncology, neurology, and immunology. Its product portfolio includes medications like SPIRIVA for respiratory diseases, PRADAXA (an oral anticoagulant), and diabetes treatments SYNJARDY and JENTADUETO. Boehringer Ingelheim has a robust research pipeline, with approximately 50% dedicated to biopharmaceuticals and the other half focusing on small molecules. The Animal Health business offers a wide range of vaccines, parasite control products, and therapeutics for pets, horses, and livestock. Boehringer Ingelheim's animal health division has been operating for over a century, with deep roots in the US. In the Biopharmaceutical Contract Manufacturing division, the company provides customized solutions for the development and manufacturing of biologic drugs. It operates advanced facilities like the Biologicals Development Centre (BDC) in Biberach, Germany, which consolidates research, development, and production capabilities for biopharmaceuticals. Boehringer Ingelheim has made significant investments in expanding its global biopharmaceutical development network, including a new chemical innovation plant (CIP) in Ingelheim that will enhance the company's capabilities for producing active pharmaceutical ingredients for clinical trials. As of 2024, Boehringer Ingelheim employed over 53,000 people worldwide and served more than 130 markets.